Novo Nordisk (NVO) shares gained regulatory momentum after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended once-weekly Sogroya for children with idiopathic short stature and persistent growth problems. The stock traded at $43.24, gaining 0.12% after recovering from a sharp mid-morning decline. The endorsement clears an important European regulatory hurdle for the Danish pharmaceutical company's long-acting growth hormone therapy and could significantly expand the treatment's reach across Europe if regulators grant final marketing approval.

Sogroya Secures Key CHMP Backing

The CHMP's positive opinion advances Novo Nordisk's effort to secure another European indication for the treatment. Idiopathic short stature affects children who remain significantly shorter than their peers without an identifiable underlying medical cause. The condition affects up to 3% of children worldwide, but diagnosis and treatment options remain limited in several regions. Many children are referred late, which can shorten the available treatment window before growth slows during adolescence. Broader recognition of the condition could therefore support earlier diagnosis and give families clearer treatment pathways.

Once-Weekly Dosing by Design

Novo Nordisk developed Sogroya as a once-weekly injection that uses albumin-binding technology to extend the drug's activity inside the body. This design reduces injection frequency compared with traditional growth hormone treatments, which patients may receive every day. Daily injection routines can be demanding for young patients, a practical challenge that has driven industry efforts to develop longer-acting growth hormone options. For eligible children and their families, the therapy could offer a simpler dosing schedule.

REAL8 Trial Data Support the Filing

Novo Nordisk backed the latest regulatory submission with findings from its REAL8 clinical trial, which assessed Sogroya in children with idiopathic short stature and other conditions linked to impaired growth. During the 52-week study period, researchers compared the once-weekly treatment with standard daily growth hormone therapy.

Trial results showed that Sogroya achieved comparable annualized height growth to daily growth hormone treatment after 52 weeks. The findings covered children with idiopathic short stature, Noonan syndrome, and those born small for gestational age, providing the clinical basis for the CHMP's positive recommendation on the additional pediatric indications.

Sogroya already holds European authorization for treating growth hormone deficiency in both adults and children. European regulators approved the treatment for adults in March 2021 and expanded approval to children in July 2023. The latest recommendation could broaden the drug's role beyond growth hormone deficiency into additional causes of short stature.

European Commission Decision Is the Next Step

The CHMP previously recommended Sogroya for Noonan syndrome and for children born small for gestational age in May 2026. The new opinion adds idiopathic short stature to the proposed expansion of the treatment's European authorization. Novo Nordisk expects the European Commission to decide on all three proposed indications later in 2026. In the EU's centralized procedure, the CHMP's opinion is the final scientific assessment before the Commission decides whether to grant a marketing authorization that applies across member states, and that upcoming decision will determine whether the once-weekly option becomes available for these additional pediatric growth conditions.

Children born small for gestational age may have reduced weight, length, or head circumference compared with expected birth measurements. Most of these children later reach normal growth levels, although some fail to achieve adequate catch-up growth during early childhood. Doctors may refer them to pediatric endocrinologists when growth remains limited after two or three years.

Idiopathic short stature can also create social and emotional challenges when children remain significantly shorter than their peers, although a medical diagnosis requires doctors to exclude other possible causes before confirming the condition. Final European approval would make Sogroya the first growth hormone specifically approved for idiopathic short stature across the European Union.

This article was first published by Blockonomi.